Cash transfers have shown promise in preventing intimate partner violence, and in reducing recipients' stress levels. Cash transfers with behavioral or psychological interventions have shown limited effectiveness at reducing stress in some African countries. Little is known of the cost-effectiveness of interventions delivered alongside cash transfer programs. The MEWE economic evaluation sub-study (MEWE-EE) runs alongside MEWE, a three-arm cluster-randomized controlled trial in Sindh, Pakistan. MEWE-EE will assess the costs and cost-effectiveness of delivering a cash-transfer program (BISP-CT) combined with a life-skills building curriculum (LSB curriculum), compared to the BISP-CT alone. The LSB curriculum is offered to either women who receive BISP-CT, or to women who receive BISP-CT and their husbands.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,536
The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions. All male study participants attending LSB curriculum classes are married to BISP-CT clients. For men, the MEWE intervention provides access to the LSB curriculum only.
The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions. All female study participants attending LSB curriculum classes are BISP-CT clients. For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs.
The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
Mirpur Sakro
Thatta, Sindh, Pakistan
Incremental cost incurred per disability adjusted life year (DALY) averted: provider perspective
Incremental cost per disability-adjusted life year (DALY) averted by the intervention compared to the control group from a provider perspective at 12 months from baseline. DALYs and costs will also be modelled up to a ten-year horizon using a Markov model.
Time frame: 12 months post randomisation
Incremental cost incurred per disability adjusted life year (DALY) averted: societal perspective
Incremental cost per disability-adjusted life year (DALY) averted by the intervention compared to the control group from a societal perspective at 12 months from baseline. DALYs and costs will also be modelled up to a ten-year horizon using a Markov model.
Time frame: 12 months post randomisation
Mean cost of intervention delivery
Cost of intervention delivery for different intervention models per patient, by category, annuitised
Time frame: 12 months post randomisation
Mean cost of LSB session
Average cost of LSB session delivery for different intervention models, annuitised
Time frame: 12 months post randomisation
Total incremental cost of the intervention in a research setting
Total additional cost of the intervention compared to the BISP-CT only for the study population and by intervention type during the research period.
Time frame: 12 months post randomisation
Total incremental cost of the intervention in the modelling cohort
Total additional cost of the intervention for the modelling cohort by intervention type over a ten-year period.
Time frame: 12 months post randomisation
Incremental cost incurred per disability adjusted life year (DALY) averted at scale: provider perspective
Incremental cost per disability-adjusted life year (DALY) averted by the intervention compared to the control group from a provider perspective at scale.
Time frame: 12 months post randomisation
Incremental cost incurred per disability adjusted life year (DALY) averted at scale: societal perspective
Incremental cost per disability-adjusted life year (DALY) averted by the intervention compared to the control group from a societal perspective at scale.
Time frame: 12 months post randomisation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.